Bibi Sedigheh Fazly Bazzaz1, Bahman Khameneh2, Hamed Zarei3, Shiva Golmohammadzadeh4. 1. Biotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. 2. Department of Pharmaceutical Control, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. 3. Students Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran. 4. Nanotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: Golmohamadzadehsh@mums.ac.ir.
Abstract
OBJECTIVE: The aim of the present study was to assess the in vitro anti-biofilm activities of solid lipid nanoparticles (SLN) loaded with rifampin against biofilm-producing Staphylococcus epidermidis. METHODS: SLN were prepared and characterized for size, zeta potentials and encapsulation efficacy. The morphological and thermal properties of formulation were evaluated by TEM imagining and DSC analysis. The anti-biofilm activity of different formulations was assessed at different incubation times and concentrations by crystal violet (CV) and viable biofilm count methods. RESULTS: The zeta potentials, particle sizes and encapsulation efficiencies of final formulations were 17 ± 0.7 mV, 101 ± 4.7 nm and approximately 70%; respectively. Rifampin-SLN was able to reduce the biomass of biofilm at time- and concentration-dependent manner. According to biofilm count results, the Rifampin-SLN was more effective for removal of the bacteria with respect to free rifampin. CONCLUSION: The results of this study highlight the advantages and efficiency of Rifampin-SLN in biofilm eradication.
OBJECTIVE: The aim of the present study was to assess the in vitro anti-biofilm activities of solid lipid nanoparticles (SLN) loaded with rifampin against biofilm-producing Staphylococcus epidermidis. METHODS: SLN were prepared and characterized for size, zeta potentials and encapsulation efficacy. The morphological and thermal properties of formulation were evaluated by TEM imagining and DSC analysis. The anti-biofilm activity of different formulations was assessed at different incubation times and concentrations by crystal violet (CV) and viable biofilm count methods. RESULTS: The zeta potentials, particle sizes and encapsulation efficiencies of final formulations were 17 ± 0.7 mV, 101 ± 4.7 nm and approximately 70%; respectively. Rifampin-SLN was able to reduce the biomass of biofilm at time- and concentration-dependent manner. According to biofilm count results, the Rifampin-SLN was more effective for removal of the bacteria with respect to free rifampin. CONCLUSION: The results of this study highlight the advantages and efficiency of Rifampin-SLN in biofilm eradication.
Authors: Seyed Mostafa Hosseini; Abbas Farmany; Mohammad Yousef Alikhani; Mohammad Taheri; Sara Soleimani Asl; Saeed Alamian; Mohammad Reza Arabestani Journal: Front Chem Date: 2022-05-11 Impact factor: 5.545